Crossject announces it has concluded a commercialization agreement in northern Europe for its innovative rescue therapy for epileptic seizures ZEPIZURE(R), previously known as ZENEO(R) Midazolam, covering Germany, the UK, Denmark, Sweden, Finland and Norway. Under the terms of the agreement, with an undisclosed strategic partner, Crossject will receive milestone payments of up to EUR1 million in total, upon marketing authorizations granted in the territories. Crossject will sell ZEPIZURE(R) with a markup that is a share of the gross margin (net sales minus cost of goods).Crossject covers regulatory development costs and owns potential marketing authorizations, while Crossject's partner controls and is responsible for all commercial costs.